Opus Genetics (IRD) Q4 2024 earnings summary

Executive summary

• Completed transformative acquisition of privately held Opus Genetics in October 2024, expanding the gene therapy pipeline for inherited retinal diseases (IRDs).

• Raised $21.5 million in March 2025 through a public offering and private placement, supplementing a year-end cash balance of $30.3 million.

• Focused on advancing two lead gene therapy candidates, OPGX-LCA5 and OPGX-BEST1, with multiple clinical milestones expected in 2025.

• Strengthened Board of Directors and enhanced strategic direction following the acquisition.

Financial highlights

• Cash and cash equivalents were $30.3 million as of December 31, 2024, with additional $21.5 million raised in March 2025, bringing available cash to $50.7 million.

• License and collaborations revenue was $11.0 million for 2024, down from $19.0 million in 2023 due to a prior year milestone payment.

• General and administrative expenses rose to $18.2 million in 2024 from $12.0 million in 2023, mainly due to acquisition-related costs and increased payroll.

• Research and development expenses increased to $26.9 million in 2024 from $17.7 million in 2023, driven by clinical trial and manufacturing costs.

• Net loss for 2024 was $57.5 million, or ($2.15) per share, compared to a net loss of $10.0 million, or ($0.46) per share, in 2023.

Outlook and guidance

• Cash runway expected to fund operations into the second half of 2026.

• Up to four clinical trial data readouts anticipated in 2025, including Phase 3 data for Phentolamine Ophthalmic Solution 0.75% in presbyopia and dim light vision disturbances.

• OPGX-BEST1 Phase 1/2 trial initiation planned for 2025, with preliminary data expected by Q1 2026.

• Continued focus on advancing IRD gene therapy pipeline and seeking strategic partners for late-stage assets.